Celecoxib

Caldwell B. , Aldington S. , Weatherall M. , Shirtcliffe P. , Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132–40

Hernandez-Diaz S. , Varas-Lorenzo C. , Garcia Rodriguez L.A. Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266–74

Simon L. , White W. , MacDonald T. , Pan S. , Rosenstein R. , Gaffney M. Cardiovascular safety of CELEBREX: a meta-analysis of 41 clinical studies in 44,308 patients. American College of Rheumatology (ACR) annual scientific meeting 12–17 November 2005. Atlanta: ACR, 2006

US Food and Drugs Administration CLASS Advisory Committee Briefing Document. [http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_01_searle.pdf] Accessed 15 May 2006

White W.B. , Faich G. , Whelton A. . Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30